The COVID-19 pandemic continues to affect millions of people across the world . The current global statistics for the disease are 111 million cases and 2.45 million deaths, with new cases emerging each day . Although several drugs including remdesivir have been approved for emergency use, they remain ineffective in bringing the infection under control . Therefore, there is a need for highly effective and safe vaccines against COVID-19 . The recent advancements in mRNA vaccines have catapulted them to be forefront in the race to develop vaccines for COVID-19 . Two mRNA vaccines, BNT162b2 and mRNA-1273, developed by Pfizer-BioNTech and Moderna Therapeutics, respectively, have been granted authorization for emergency use by the US Food and Drug Administration . Interim analysis of the clinical trials for BNT162b2 and mRNA-1273 vaccines reported an efficacy of 95% and 94.1%, respectively, after the second dose . The adverse events for both the vaccines have been found to be mild to moderate, with mostly injection-site reactions and fatigue . No serious adverse events have been reported . Moreover, Pfizer-BioNTech and Moderna Therapeutics have announced that their vaccines are effective even against the new strains (B.1.17 and B.1.351) of the virus . Both companies are now scaling up the production of the vaccines to meet the global demand . Although the long-term efficacy, safety, and immunogenicity of these vaccines is uncertain, there is hope that they can turn the tables against COVID-19 in this current pandemic situation.